RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

RAYUS Radiology reports, CDI Quality Institute, a non-profit affiliate, one of the nation’s leading national subspecialty providers for advanced diagnostic and interventional radiology services, once again qualified as a Provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program with the Centers for Medicare & Medicaid Services (CMS).

PLE designation from CMS, the largest healthcare payor in the United States, is granted to a select group of organizations nationwide who are tasked with providing real-time clinical guidance to treating physicians ordering diagnostic imaging procedures such as MRI, CT and PET exams. Currently, only 22 federally qualified organizations nationwide hold the notable designation that the Quality Institute first earned in 2016.

The Quality Institute is supported by more than 250 sub-specialty trained radiologists and top specialists within RAYUS’ growing nationwide network. Since its inception in 2003, the Quality Institute has helped define quality measures to ensure patients receive the right diagnostic test or radiological procedure at the right time and, in turn, reduce any unnecessary care – and unnecessary health care spend.

“We are privileged to be among such an illustrious and highly skilled group of pioneers in the development of appropriate use criteria for diagnostic imaging,” said RAYUS Radiology Chief Executive Officer Kim Tzoumakas. “The RAYUS nationwide network of clinical experts is growing rapidly and, as a result, the evidence-based knowledge that contributes to our ability to help provide the highest quality care is growing along with us.”

Starting in 2023, if a newly released draft rule is enacted as written, all clinicians will be required to consult AUC, like those developed by the RAYUS Quality Institute, when ordering the most advanced imaging tests (MRI and CT) under Medicare coverage guidelines.

The RAYUS Quality Institute and its robust clinical library provide high-level quality support to the physician, medical center and research communities, including providing summary criteria documents distributed to ordering physicians and producing The Consult, a quarterly publication of the Quality Institute for clinicians.  Additionally, developed criteria are licensed to AIM Specialty Health, a subsidiary of Anthem, that serves more than 52M members and 330K ordering physicians nationwide, and Infinx Healthcare.

“All of us involved with our Quality Institute’s work in providing best-practice utilization guidelines and other clinical decision support tools are proud to be an important resource to our radiologists, our referring physicians, and our patients in continuing to advance the level of care,” said Dr. Thomas Gilbert, RAYUS Radiology’s Chief Clinical Officer.

Both the Quality Institute and the affiliated RAYUS Radiology network grew from the well-established roots of the former Center for Diagnostic Imaging (CDI). CDI became RAYUS Radiology in June as part of national rebranding and associated ‘SHINE ON’ campaign celebrating CDI’s distinguished 40-year legacy in the radiological field, its people and the ongoing national growth and expansion planned for the network.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.